Eli Lilly at 41 Times Earnings: What the Tirzepatide Franchise Has to Deliver
Eli Lilly closed at USD 1,220.28 on the US market on 12 August 2026. Applied to trailing twelve-month earnings per share, that gives a price-to-earnings ratio of about 41.0. A ratio of 41 is neither expensive nor cheap on its own. What it means depends on the growth it assumes. This article takes that assumption apart: where the revenue comes from, what raises it and what erodes it, and which conditions would have to fail for the assumption to break down. Table of Contents What Eli Lilly's Valuation Assumes The Structure and Requirements of the Tirzepatide Business What the Revenue Data Shows The Conditions That Keep the Growth Premium in Place How Eli Lilly Differs From Novo Nordisk Limits of the Investment Case Frequently Asked Questions Summary 1. What Eli Lilly's Valuation Assumes The price-to-earnings ratio divides the share price by earnings per share. The closing price of USD 1,220.28 on 12 August 2026 and trailing twelve-month earnings per share of US...